Coronary Microcirculation Dysfunction
Conditions
Interventions
Intervention group:received a complete ECP course based on the second-stage preventive drug treatment for coronary heart disease
Sponsors
The Eighth Affiliated Hospital, Sun Yat-sen University
Eligibility
Sex/Gender
All
Age
25 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Aged 25-70 years old; 2. Coronary angiography shows that the QCA stenosis of the main branches of the left and right coronary arteries is less than 50%, and the FFR of 50-90% of the lesions measured by pressure wire is = 0.8, without the need for intervention treatment; 3. After PCI, the distal blood flow was TIMI3, and the FFR = 0.8 was required for stenosis in the stent, so no interventional treatment was required; 4.There was no history of cardiac muscle disease, and cardiac ultrasound showed no significant thickening (IVSD and lvpwd = 12mm) or thinning (IVSD and lvpwd = 8mm); 5. Can accept and cooperate with more than half a year of follow-up; 6. Informed consent form approved by the Ethics Committee.
Exclusion criteria
Exclusion criteria: 1.Coronary angiography with or without coronary stent and QCA showed coronary stenosis = 90%, or coronary stenosis <90% and ffr<0.8; 2. Acute coronary syndrome or cardiac insufficiency (nyhf class III-IV); 3.The subject was complicated with myocardial disease; 4.Unable to tolerate CMR; 5.Subject is allergic to adenosine triphosphate or adenosine; 6. Significant aortic regurgitation, aortic aneurysm, and dissection aneurysm; 7. Coronary artery spasm or severe coronary aneurysm; 8. Symptomatic congestive heart failure; 9. Heart valve disease, congenital heart disease, cardiomyopathy; 10. Cerebral hemorrhage within half a year, hemorrhagic disease or clear bleeding tendency; 11. Lower extremity infection, phlebitis, severe varicose veins, deep vein thrombosis; 12. Progressive malignancy or serious disease with poor prognosis; 13. Systolic blood pressure =180mmHg, or diastolic blood pressure =110mmHg when randomly grouped; 14. Severe arrhythmia affecting ECP therapy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Myocardial perfusion of CMR in patients with CMD; | — |
Secondary
| Measure | Time frame |
|---|---|
| Differences in activity tolerance index between two groups of patients ;Differences in cardiac function (heart ultrasound) between the two groups ;Differences in blood glucose between the two groups ;Differences in blood lipids between two groups of patients after six months ; | — |
Countries
China
Contacts
Public ContactJianwen Liang
The Eighth Affiliated Hospital, Sun Yat-sen University
Outcome results
None listed